Sanofi-Aventis has acquired Zentiva N.V.
Sanofi-Aventis has successfully completed and settled the voluntary tender offer for all of Zentiva N.V.'s shares. Total value of this transaction is over US$2 billion.
Sanofi-Aventis, a leading global pharmaceutical company, discovers, develops and distributes a broad offering of medicines, vaccines and integrated healthcare solutions adapted to local needs and means. Sanofi-Aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Zentiva N.V. is an international pharmaceutical company focused on developing, manufacturing and marketing modern generic pharmaceutical products. The company has leading positions in the pharmaceutical markets in the Czech Republic, Slovakia, Romania and Turkey, and is growing rapidly in Poland, Russia, Bulgaria, Hungary, the Ukraine and the Baltic States.
Oaklins' team in the Czech Republic acted as the tender agent to Sanofi-Aventis in relation to the voluntary tender offer for all of Zentiva N.V.'s shares. From July 2008 to March 2009, the Czech team arranged the purchase of approximately 70% of the issued share capital of Zentiva.
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreSLT has been acquired by Indutrade
SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.
Learn more